产品名称：Monoclonal Antibody to Human SC5b-9 (Neoantigen)

产品介绍
品名	Monoclonal Antibody to Human SC5b-9 (Neoantigen)
货号	A239
规格	100 µL
同种型	IgG2ak
蛋白质浓度	> 1.0 mg/mL
纯度	≥ 95% by SDS PAGE
缓冲液	Borate Buffered Saline (pH 8.4 ± 0.2)
物种交叉反应	Human, baboon, Cynomologus macaque, Rhesus macaque.
储存	≤ 30 Days 2-8˚C  > 30 Days ≤ –20˚C
应用	EIA、FACS、IHC、WB、IF
使用说明	For Research Use Only. Not for use in diagnostic procedures.
产品描述	A murine monoclonal antibody to a neoantigen on the terminal complement complex. This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.
背景	The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC
特异性	The specificity of the monoclonal antibody was established via a series of immunoassays. First, the antibody was shown by ELISA to bind SC5b-9 and C9 immobilized in microtiter wells, but not to immobilized C3, C5, C6, C7, C8 or S protein. Immobilized C9 is known to express antigenic determinates in common with polymeric C9. Second, free (unbound) SC5b-9, free (unbound) C9 and zymosan-activated human serum were shown (via inhibition EIA) to inhibit the binding of this antibody to immobilized SC5b-9. Subsequently, the antibody was shown to bind complement lysed sheep and rabbit erythrocytes (both of which contain TCC). The antibody therefore binds polymerized C9 present in both SC5b-9 and MAC, the two major forms of TCC.
应用
参考资料	Merri, A., Junnikala, S. Exceptional Resistance of Human H2 Gioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein 1, J Immunol 164:11 6075-6081, 2000. Stoltzner, S., Lemerre, C. et al. Temporal accrual of complement proteins in Amyloid plaques in patients with down's syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000. Wright, A., Morrison, S. Effect of C2 Associated Carbohydrate structure of Ig Effector function: studies with chimeric mouse human IgG1 Antibodies in glycosylation mutants of chinese hamster ovary cells, J. Immunol 160:3393-3402, 1998. Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997. Rogers, J., N. Cooper, et al. Complement Activation by ß-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.